A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group
Overall, the findings support the efficacy and safety of teclistamab in patients with RRMM and RI, highlighting the need for prospective clinical trials to optimize the treatment strategies for this population.
Authors
- Christopher Sun Strouse (ORCID: https://orcid.org/0000-0003-4964-167X)
- Abdullah Khan (ORCID: https://orcid.org/0000-0003-2166-2583)
- Zahra Mahmoudjafari (ORCID: https://orcid.org/0000-0002-3168-2521)
- Marshall McKenna
- Shebli Atrash (ORCID: https://orcid.org/0000-0003-4547-7534)
- Prerna Mewawalla (ORCID: https://orcid.org/0009-0008-7464-6898)
- Jordan Andrew Snyder (ORCID: https://orcid.org/0000-0002-1001-134X)
- Reed Friend
- Kimberly M Green (ORCID: https://orcid.org/0009-0003-1150-5506)
- Mehak M Laharwal (ORCID: https://orcid.org/0000-0003-3898-1927)
- Mansi Shah (ORCID: https://orcid.org/0000-0001-6993-503X)
- Ahmed Nausheen
- Alma Habib (ORCID: https://orcid.org/0000-0003-4429-3602)
- Hira Shaikh
- Yun Kyuong Ryu Tiger
- Muhammad Umair Mushtaq
- Barry Paul
- Maha Hameed
- Al-Ola Abdallah
Institutions
- Rutgers, The State University of New Jersey (US)
- Florida State University (US)
- University of Iowa (US)
- Allegheny Health Network (US)
- Medical University of South Carolina (US)
- Levine Cancer Institute (US)
- University of Kansas Medical Center (US)
- Sarasota University (US)
- The Ohio State University (US)
- University of South Florida Sarasota–Manatee (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3390/cancers18050740
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00